US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Direxion Daily S&P Biotech Bull 3x Shares

243.09

+20.099.01%

Post-market: 242.20-0.8900-0.37%16:49 EDT

Volume:605.18K

Turnover:144.31M

Market Cap:637.99M

PE:- -

High:246.22

Open:223.71

Low:222.45

Close:223.00

52wk High:341.93

52wk Low:102.35

Shares:2.62M

Float Shares:2.62M

Volume Ratio:1.01

T/O Rate:23.06%

Dividend:0.91

Dividend Rate:0.38%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Abbott announces U.S. commercial launch of SimpleScreen CRC

Celcuity Announces That REVTORPYK™ (gedatolisib) Is Now Commercially Available In The United States

CeriBell Receives FDA Clearance for Platform Software Update

MT Newswires Live

Tiziana Life Sciences Seeks FDA Orphan Status for Intranasal Foralumab in Multiple System Atrophy

Ceribell receives FDA 510k clearance of quantitative EEG trending, analysis

Tiziana Life Sciences Files for Orphan Drug Designation with the FDA for Intranasal Foralumab for the Treatment of Multiple System Atrophy (MSA)

Ceribell Receives FDA 510(k) Clearance for Quantitative EEG Trending and Amplitude-Integrated EEG Analysis

Aldeyra Therapeutics: Neutral Rating Maintained Amid FDA Uncertainty; $2 Price Target Reaffirmed

Roche’s Genentech announces FDA approves NDA for fenebrutinib

Analysts Are Bullish on Top Healthcare Stocks: Abbott Laboratories (ABT), Tectonic Therapeutic (TECX)

Health Care Roundup: Market Talk

Yamashita Health Care Sees FY Net Y553.00m

HUTCHMED Shares Rise Over 3% After Announcing FDA Submission for Orpathys and Tagrisso Combination Therapy

IHH Healthcare's Recent Weakness Likely Offers a Buying Opportunity

Golden Globe Resources Sets Date and Digital Framework for 2026 AGM

Vectus wins FDA pre-IND green light for VB0004 in IPF

Telix Wins FDA Fast Track for Pre-Biopsy Prostate Cancer Imaging Program

DBV Technologies submits BLA to FDA for Viaskin Peanut Patch

DBV Technologies Announces Submission of Biologics License Application to U.S. FDA for the VIASKIN® Peanut Patch in Children Aged 4-7 Years

Healthcare Stocks Declined as Consumer Confidence Slips

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/LABU/news?page=16"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"LABU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LABU\",,,,,undefined,":{"symbol":"LABU","market":"US","secType":"STK","nameCN":"Direxion Daily S&P Biotech Bull 3x Shares","latestPrice":243.09,"timestamp":1791576000000,"preClose":223,"halted":0,"volume":605179,"hourTrading":{"tag":"盘后","latestPrice":242.2,"preClose":243.09,"latestTime":"16:49 EDT","volume":830,"amount":201076.6715,"timestamp":1791578959089,"change":-0.89,"changeRate":-0.003661,"amplitude":0.004484},"delay":0,"changeRate":0.09008968609865473,"floatShares":2624500,"shares":2624500,"eps":0,"marketStatus":"Post-Mkt","change":20.09,"latestTime":"10-09 16:51:58 EDT","open":223.71,"high":246.22,"low":222.45,"amount":144310094.72687,"amplitude":0.106592,"askPrice":243.2,"askSize":400,"bidPrice":241.2,"bidSize":400,"shortable":3,"etf":3,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1791590400000},"marketStatusCode":4,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":223,"sharesOutstanding":3074486,"nav":227.52,"aum":597123938.28,"dividendRate":0.003761,"bidAskSpread":0.003146,"preHourTrading":{"tag":"盘前","latestPrice":223.28,"preClose":223,"latestTime":"09:28 EDT","volume":2212,"amount":498293.87776,"timestamp":1791552512789,"change":0.28,"changeRate":0.001256,"amplitude":0.01487},"postHourTrading":{"tag":"盘后","latestPrice":242.2,"preClose":243.09,"latestTime":"16:49 EDT","volume":830,"amount":201076.6715,"timestamp":1791578959089,"change":-0.89,"changeRate":-0.003661,"amplitude":0.004484},"volumeRatio":1.009489,"impliedVol":0.9666,"impliedVolPercentile":0.7052},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LABU\",,,,,undefined,":{"symbol":"LABU","floatShares":2624500,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.009489,"shares":2624500,"dividePrice":0.9143,"high":246.22,"amplitude":0.106592,"preClose":223,"low":222.45,"week52Low":102.3547,"pbRate":"--","week52High":341.93,"institutionHeld":0,"latestPrice":243.09,"eps":0,"divideRate":0.003761,"volume":605179,"delay":0,"ttmEps":0,"open":223.71,"prevYearClose":159.39,"prevWeekClose":248.72,"prevMonthClose":265.79,"prevQuarterClose":265.79,"fiveDayClose":248.72,"twentyDayClose":261.3,"sixtyDayClose":254.8},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LABU\",params:#limit:5,,,undefined,":[{"date":"2025-09-23","symbol":"LABU","amount":0.10273,"announcedDate":"2025-09-22","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-23","defaultRemindTime":1758634200000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-30","payableDate":"2025-09-23","currency":"USD","dateTimestamp":1758600000000,"payDate":"2025-09-30"},{"date":"2025-06-24","symbol":"LABU","amount":0.21897,"announcedDate":"2025-06-23","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-24","defaultRemindTime":1750771800000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-07-01","payableDate":"2025-06-24","currency":"USD","dateTimestamp":1750737600000,"payDate":"2025-07-01"},{"date":"2025-03-25","symbol":"LABU","amount":0.10714,"announcedDate":"2025-03-24","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-25","defaultRemindTime":1742909400000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-01","payableDate":"2025-03-25","currency":"USD","dateTimestamp":1742875200000,"payDate":"2025-04-01"},{"date":"2024-06-25","symbol":"LABU","amount":0.15021,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-06-25","defaultRemindTime":1719322200000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-07-02","payableDate":"2024-06-25","currency":"USD","dateTimestamp":1719288000000,"payDate":"2024-07-02"},{"date":"2024-03-19","symbol":"LABU","amount":0.16064,"announcedDate":"2024-03-18","type":"dividend","market":"US","newRecordDate":"2024-03-20","defaultRemindTime":1710855000000,"name":"三倍做多标普生物-Direxion","recordDate":"2024-03-26","payableDate":"2024-03-20","currency":"USD","dateTimestamp":1710820800000,"payDate":"2024-03-26"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LABU\",market:\"US\",,,undefined,":[{"executeDate":"2018-06-19","recordDate":"2018-06-20","paymentDate":"2018-06-26","value":0.01932,"currency":"USD"},{"executeDate":"2018-09-25","recordDate":"2018-09-26","paymentDate":"2018-10-02","value":0.0954,"currency":"USD"},{"executeDate":"2018-12-27","recordDate":"2018-12-28","paymentDate":"2019-01-04","value":0.09621,"currency":"USD"},{"executeDate":"2019-03-19","recordDate":"2019-03-20","paymentDate":"2019-03-26","value":0.10973,"currency":"USD"},{"executeDate":"2019-06-25","recordDate":"2019-06-26","paymentDate":"2019-07-02","value":0.03745,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LABU\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LABU\",pageSize:20,pageCount:16,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2671204888","title":"Abbott announces U.S. commercial launch of SimpleScreen CRC","url":"https://stock-news.laohu8.com/highlight/detail?id=2671204888","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671204888?lang=en_us&edition=fundamental","pubTime":"2026-09-30 20:06","pubTimestamp":1790769961,"startTime":"0","endTime":"0","summary":"Abbott (ABT) announced the U.S. commercial launch of SimpleScreen CRC, an FDA-approved blood-based colorectal cancer screening test for adults age ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/abbott-announces-u-s-commercial-launch-of-simplescreen-crc-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/abbott-announces-u-s-commercial-launch-of-simplescreen-crc-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1914381329.SGD","IHI","BK4504","LU1721429741.USD","LU2133065610.SGD","LU0211331839.USD","LU0114720955.EUR","LU0320765489.SGD","LU0456854461.SGD","LABU","TMED","LU1670627923.USD","LU2468319806.SGD","LU1023059063.AUD","LU0266013472.USD","LU0208291251.USD","ABT","CRC","LU2089984988.USD","LU1057294990.SGD","PJP","LU1691799644.USD","LU2324357040.USD","IE0009355771.USD","IE00BFTCPJ56.SGD","LU0882574055.USD","SG9999002224.SGD","BK4213","BK4592","LU1989763427.SGD","LU0432979614.USD","IE00B2B36J28.USD","SG9999002232.USD","LU2211815571.USD","SG9999004303.SGD","SGXZ23171101.USD","IE0002141913.USD","LU2237957811.SGD","LU1670628061.USD","LU1721429402.USD","LU2112291526.USD","LU0070302665.USD","LU0234572021.USD","BK4588","BK4581","LU0058720904.USD","BK4082","LU0266512127.USD","IE00BJT1NW94.SGD","LU1989763690.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671253201","title":"Celcuity Announces That REVTORPYK™ (gedatolisib) Is Now Commercially Available In The United States","url":"https://stock-news.laohu8.com/highlight/detail?id=2671253201","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671253201?lang=en_us&edition=fundamental","pubTime":"2026-09-30 20:00","pubTimestamp":1790769600,"startTime":"0","endTime":"0","summary":"REVTORPYK (gedatolisib)   REVTORPYK (gedatolisib) vial and box  REVTORPYK is indicated for patients with HR+/HER2- advanced breast cancer without a PIK3CA mutation detected following progression on or","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/30/3371842/0/en/celcuity-announces-that-revtorpyk-gedatolisib-is-now-commercially-available-in-the-united-states.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SRET","IDNA","BK4599","BK4203","BK4585","LU1878469433.USD","ALT","BK4588","NVIB","UBCP","BK4139","LABU","BK4225","HR","BK4211","GDOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671220950","title":"CeriBell Receives FDA Clearance for Platform Software Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2671220950","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671220950?lang=en_us&edition=fundamental","pubTime":"2026-09-30 19:32","pubTimestamp":1790767962,"startTime":"0","endTime":"0","summary":"CeriBell (CBLL) has received the US Food and Drug Administration's approval for a software update that will add three capabilities to its namesake platform, the company said Wednesday.The new capabili","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4082","BK4588","BK4585","CBLL","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671209180","title":"Tiziana Life Sciences Seeks FDA Orphan Status for Intranasal Foralumab in Multiple System Atrophy","url":"https://stock-news.laohu8.com/highlight/detail?id=2671209180","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671209180?lang=en_us&edition=fundamental","pubTime":"2026-09-30 19:28","pubTimestamp":1790767704,"startTime":"0","endTime":"0","summary":"An update from Tiziana Life Sciences ( ($TLSA) ) is now available. On September 30, 2026, Tiziana Life Sciences announced it has filed a request wi...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/tiziana-life-sciences-seeks-fda-orphan-status-for-intranasal-foralumab-in-multiple-system-atrophy?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/tiziana-life-sciences-seeks-fda-orphan-status-for-intranasal-foralumab-in-multiple-system-atrophy?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LABU","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671209919","title":"Ceribell receives FDA 510k clearance of quantitative EEG trending, analysis","url":"https://stock-news.laohu8.com/highlight/detail?id=2671209919","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671209919?lang=en_us&edition=fundamental","pubTime":"2026-09-30 19:20","pubTimestamp":1790767236,"startTime":"0","endTime":"0","summary":"CeriBell (CBLL) announced that the U.S. Food and Drug Administration, FDA, has cleared new software for the Ceribell System that “makes it easier a...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ceribell-receives-fda-510k-clearance-of-quantitative-eeg-trending-analysis-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ceribell-receives-fda-510k-clearance-of-quantitative-eeg-trending-analysis-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["QQH","IGM","BK4082","BK4585","CBLL","BK4588","VGT","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671280201","title":"Tiziana Life Sciences Files for Orphan Drug Designation with the FDA for Intranasal Foralumab for the Treatment of Multiple System Atrophy (MSA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2671280201","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671280201?lang=en_us&edition=fundamental","pubTime":"2026-09-30 19:00","pubTimestamp":1790766000,"startTime":"0","endTime":"0","summary":"BOSTON, Sept.  30, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq:TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/30/3371756/0/en/tiziana-life-sciences-files-for-orphan-drug-designation-with-the-fda-for-intranasal-foralumab-for-the-treatment-of-multiple-system-atrophy-msa.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1121112475.USD","LU2506951875.HKD","MSA","BK4183","LU0426417589.USD","LU1430594728.SGD","LU2506952170.USD","BK4085","LU2247934214.USD","ODD","LU0950375773.USD","LU2125909759.SGD","LABU","LU2211815571.USD","BK4577","LU2125909916.SGD","BK4585","LU1585245621.USD","BK4588","LU1043141123.HKD","LU1923622291.USD","LU1043141396.HKD","BK4533","LU0823417737.USD","LU0994945656.USD","LU0640476718.USD","BNGE","LU2506952097.USD","EA","LU1280957306.USD","NERD","LU0154245756.USD","LU0006061336.USD","ESPO","BK4143","LU0053671581.USD","BK4532","HERO","LU0426412945.USD","LU2506951958.HKD","LU1815336091.USD","LU0823417653.USD","LU0154245673.USD","LU0757428866.USD","IE0009354923.USD","LU0728928796.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671220149","title":"Ceribell Receives FDA 510(k) Clearance for Quantitative EEG Trending and Amplitude-Integrated EEG Analysis","url":"https://stock-news.laohu8.com/highlight/detail?id=2671220149","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671220149?lang=en_us&edition=fundamental","pubTime":"2026-09-30 19:00","pubTimestamp":1790766000,"startTime":"0","endTime":"0","summary":"New clearance to further simplify bedside EEG interpretation and enable more informed interventions for patients of all ages across multiple indicationsSUNNYVALE, Calif., Sept.  30, 2026 (GLOBE NEWSWI","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/30/3371750/0/en/ceribell-receives-fda-510-k-clearance-for-quantitative-eeg-trending-and-amplitude-integrated-eeg-analysis.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CBLL","BK4214","AMPL","LABU","BK4588","SAH","BK4082","BK4023","RA","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671205590","title":"Aldeyra Therapeutics: Neutral Rating Maintained Amid FDA Uncertainty; $2 Price Target Reaffirmed","url":"https://stock-news.laohu8.com/highlight/detail?id=2671205590","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671205590?lang=en_us&edition=fundamental","pubTime":"2026-09-30 18:25","pubTimestamp":1790763928,"startTime":"0","endTime":"0","summary":"Analyst Matthew Caufield of H.C. Wainwright reiterated a Hold rating on Aldeyra Therapeutics, retaining the price target of $2.00. Matthew Caufield...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/aldeyra-therapeutics-neutral-rating-maintained-amid-fda-uncertainty-2-price-target-reaffirmed-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/aldeyra-therapeutics-neutral-rating-maintained-amid-fda-uncertainty-2-price-target-reaffirmed-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALDX","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671220846","title":"Roche’s Genentech announces FDA approves NDA for fenebrutinib","url":"https://stock-news.laohu8.com/highlight/detail?id=2671220846","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671220846?lang=en_us&edition=fundamental","pubTime":"2026-09-30 17:50","pubTimestamp":1790761812,"startTime":"0","endTime":"0","summary":"Genentech, a member of the Roche (RHHBY) Group, announced that the U.S. FDA has accepted the company’s NDA under priority review for fenebrutinib, ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/roches-genentech-announces-fda-approves-nda-for-fenebrutinib-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/roches-genentech-announces-fda-approves-nda-for-fenebrutinib-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4585","CANC","LABU","HRTS","RHHBY","03165","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671724342","title":"Analysts Are Bullish on Top Healthcare Stocks: Abbott Laboratories (ABT), Tectonic Therapeutic (TECX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2671724342","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671724342?lang=en_us&edition=fundamental","pubTime":"2026-09-30 16:50","pubTimestamp":1790758222,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Abbott Laboratories (ABT), Tectonic Therapeutic (TEC...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-abbott-laboratories-abt-tectonic-therapeutic-tecx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-abbott-laboratories-abt-tectonic-therapeutic-tecx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0122379950.USD","TECX","LU0432979614.USD","IE0009355771.USD","LU0170899867.USD","BK4581","LU0208291251.USD","LU2237957811.SGD","TMED","LU0320765489.SGD","PJP","LU1023059063.AUD","BK4137","LU2468319806.SGD","XBI","LU0868494617.USD","SG9999002232.USD","LU0058720904.USD","LU0289739699.SGD","LU1670628061.USD","IE00B2B36J28.USD","LU0114720955.EUR","IE00BJJMRZ35.SGD","XLV","IE0002141913.USD","LU1914381329.SGD","SGXZ23171101.USD","BK4568","LU1057294990.SGD","LU0128526141.USD","BK4139","LABU","SG9999004303.SGD","LU1989763690.USD","LU1721429402.USD","IHI","LU2133065610.SGD","BK4585","LU0211331839.USD","IE00BFTCPJ56.SGD","LU1061106388.HKD","LU2112291526.USD","LU0882574055.USD","LU1721429741.USD","BK4588","HCSG","LU0266013472.USD","BK4533","LU2089984988.USD","ABT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671027487","title":"Health Care Roundup: Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2671027487","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671027487?lang=en_us&edition=fundamental","pubTime":"2026-09-30 16:20","pubTimestamp":1790756400,"startTime":"0","endTime":"0","summary":"The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET.0749 GMT - Fresenius investors might have overreacted to news th","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XBI","BK4585","PMDE","BK4581","XLV","DECU","LABU","VOTE","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671275727","title":"Yamashita Health Care Sees FY Net Y553.00m","url":"https://stock-news.laohu8.com/highlight/detail?id=2671275727","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671275727?lang=en_us&edition=fundamental","pubTime":"2026-09-30 15:00","pubTimestamp":1790751600,"startTime":"0","endTime":"0","summary":"Yamashita Health Care Holdings Inc. also released the following forecasts:. Results are based on Japanese accounting standards.This content was automatically published based on data and/or text from the original source. For feedback, write to singaporeeditors@dowjones.com.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4581","BK4585","XBI","XLV","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122605627","title":"HUTCHMED Shares Rise Over 3% After Announcing FDA Submission for Orpathys and Tagrisso Combination Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=1122605627","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1122605627?lang=en_us&edition=fundamental","pubTime":"2026-09-30 11:02","pubTimestamp":1790737370,"startTime":"0","endTime":"0","summary":"HUTCHMED (00013) shares rose more than 3%, reaching HK$23.04 as of press time, up 3.32%, with a turnover of HK$69.44 million.On September 29, HUTCHMED (00013) announced that AstraZeneca has submitted...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1587","00013","LABU","KCAI","IPOS","VXUS","BK4588","BK1191","BK4585","BK1588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671221962","title":"IHH Healthcare's Recent Weakness Likely Offers a Buying Opportunity","url":"https://stock-news.laohu8.com/highlight/detail?id=2671221962","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671221962?lang=en_us&edition=fundamental","pubTime":"2026-09-30 10:11","pubTimestamp":1790734260,"startTime":"0","endTime":"0","summary":"0211 GMT - IHH Healthcare's recent share price weakness is likely an enhanced buying opportunity, with Fortis-related litigation concerns expected to have limited impact on operations, says Citi analyst Megat Fais in a note. IHH says it isn't subject to financial claims in the dispute involving Daiichi Sankyo and former Fortis promoters. IHH's India plans remain on track to reach 10,000 beds target by 2030-2031, while Singapore's recovery is expected to continue, he reckons. Malaysia should see growth from selective bed additions and medical tourism, while Turkey's strong demand and international patient flows are expected to continue, he adds. Citi keeps a buy rating and its target price at 10.40 ringgit. Shares are 0.1% higher at 7.88 ringgit.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU0029874061.USD","LU0128526141.USD","BK4581","BK4137","XLV","BK4585","HCSG","DSNKY","BK4007","LABU","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671044225","title":"Golden Globe Resources Sets Date and Digital Framework for 2026 AGM","url":"https://stock-news.laohu8.com/highlight/detail?id=2671044225","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671044225?lang=en_us&edition=fundamental","pubTime":"2026-09-30 08:23","pubTimestamp":1790727806,"startTime":"0","endTime":"0","summary":"Reckon Health Care Holdings Ltd ( ($AU:GGR) ) has shared an announcement. Golden Globe Resources Limited has convened its 2026 Annual General Meeti...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/golden-globe-resources-sets-date-and-digital-framework-for-2026-agm?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/golden-globe-resources-sets-date-and-digital-framework-for-2026-agm?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XBI","BK4581","BK4585","BK4588","LABU","XLV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671223279","title":"Vectus wins FDA pre-IND green light for VB0004 in IPF","url":"https://stock-news.laohu8.com/highlight/detail?id=2671223279","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671223279?lang=en_us&edition=fundamental","pubTime":"2026-09-30 07:58","pubTimestamp":1790726292,"startTime":"0","endTime":"0","summary":"Vectus Biosystems Limited ( ($AU:VBS) ) has provided an announcement. Vectus Biosystems has secured a pre-Investigational New Drug Type B meeting w...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/vectus-wins-fda-pre-ind-green-light-for-vb0004-in-ipf?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/vectus-wins-fda-pre-ind-green-light-for-vb0004-in-ipf?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LABU","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671228076","title":"Telix Wins FDA Fast Track for Pre-Biopsy Prostate Cancer Imaging Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2671228076","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671228076?lang=en_us&edition=fundamental","pubTime":"2026-09-30 07:15","pubTimestamp":1790723736,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Telix Pharmaceuticals ( ($AU:TLX) ). Telix Pharmaceuticals has secured U.S. FDA Fast Track designation for its ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/telix-wins-fda-fast-track-for-pre-biopsy-prostate-cancer-imaging-program?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/telix-wins-fda-fast-track-for-pre-biopsy-prostate-cancer-imaging-program?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TLX","BK4585","BK4588","BK4139","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671228597","title":"DBV Technologies submits BLA to FDA for Viaskin Peanut Patch","url":"https://stock-news.laohu8.com/highlight/detail?id=2671228597","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671228597?lang=en_us&edition=fundamental","pubTime":"2026-09-30 06:35","pubTimestamp":1790721319,"startTime":"0","endTime":"0","summary":"DBV Technologies (DBVT) announced that the company has submitted a Biologics License Application to the U.S. FDA for the Viaskin Peanut Patch in ch...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/dbv-technologies-submits-bla-to-fda-for-viaskin-peanut-patch-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/dbv-technologies-submits-bla-to-fda-for-viaskin-peanut-patch-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4585","BK4139","DBVT","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671942228","title":"DBV Technologies Announces Submission of Biologics License Application to U.S. FDA for the VIASKIN® Peanut Patch in Children Aged 4-7 Years","url":"https://stock-news.laohu8.com/highlight/detail?id=2671942228","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671942228?lang=en_us&edition=fundamental","pubTime":"2026-09-30 06:29","pubTimestamp":1790720940,"startTime":"0","endTime":"0","summary":"Chtillon, France, September 29, 2026 DBV Technologies Announces Submission of Biologics License Application to U.S. FDA for theVIASKIN Peanut Patch in Children Aged 4-7 Years  TheBLAis supportedbyther","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/29/3371452/0/en/dbv-technologies-announces-submission-of-biologics-license-application-to-u-s-fda-for-the-viaskin-peanut-patch-in-children-aged-4-7-years.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IDNA","GDOC","HYLG","BK4585","NVIB","MEDX","BK4588","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671247293","title":"Healthcare Stocks Declined as Consumer Confidence Slips","url":"https://stock-news.laohu8.com/highlight/detail?id=2671247293","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671247293?lang=en_us&edition=fundamental","pubTime":"2026-09-30 04:58","pubTimestamp":1790715480,"startTime":"0","endTime":"0","summary":"On a losing day in Wall Street, the healthcare industry was no exemption. Stocks fell amid a surprising decline in the Conference Board Consumer Confidence Index.UniQure slid after patients treated with its Huntington's disease drug in a recent study no longer showed a statistically significant slowdown in disease-induced decline after four years. At four years, the study's primary endpoint--composite Unified Huntington's Disease Rating Scale --showed a 44% slowing of disease progression compared with an external control, but the data did not reach statistical significance, the company said.Novo Nordisk has signed a licensing deal for a weight-loss treatment being developed by Hengrui Pharma that could be worth up to $2.6 billion. The Danish drugmaker will pay China-based Hengrui $300 million upfront, with the rest of the potential deal value tied to milestones. Novo will obtain exclusive rights to develop, manufacture and commercialize HRS-1596 globally, excluding mainland China, Hong","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4581","BK4588","XLV","LU0128526141.USD","HCSG","BK4137","BK4585","XBI","LABU","LU0029874061.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":21,"pageCount":16,"totalSize":418,"code":"91000000","status":"200"}]}}